What is the typical dosing for Ipamorelin?

Doses observed in research studies. Common doses observed in research: 100-300 mcg per injection, 200-300 mcg 2-3x daily. Duration: 8-12 weeks typical. Administration: Subcutaneous injection.

Growth Hormone

Ipamorelin

Also known as: IPAM, NNC 26-0161

Clinical Trials

Buy in shop

Ipamorelin from $56/kit

3 verified vendors, ≥99% purity, COAs included.

Compare prices

Key Facts: Ipamorelin

Category: Growth Hormone
FDA Status: Not FDA Approved
Clinical Status: Investigational - Phase II trials discontinued. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)
Administration: Subcutaneous injection
Typical Dose: 200-300 mcg 2-3x daily
Frequency: 2-3x daily
Duration: 8-12 weeks typical

Also Known As

IPAM, NNC 26-0161

Mechanism of Action

Ipamorelin binds to ghrelin receptors (GHSR) in the pituitary gland, triggering growth hormone release. Unlike other GHRPs, it does not stimulate significant ACTH, cortisol, prolactin, or aldosterone release, making it highly selective for GH.

Research Summary

Phase II trials for postoperative ileus showed good safety but failed to meet efficacy endpoints and were discontinued. Research demonstrates dose-dependent GH release with minimal side effects, improved bone density in postmenopausal women, and potential benefits for muscle mass and recovery.

Trial Progress:Phase II

Pre

III

FDA

Dosing Information

Human Trials·Human studies conducted, not FDA approved

Typical DosingⓘDoses commonly used by people in practice, based on community reports and anecdotal experience.

Community experience

Common Dose

200-300 mcg 2-3x daily

Range

100-500 mcg per dose

Frequency

2-3x daily

Best taken on empty stomach. Common times: morning, post-workout, before bed. Often combined with CJC-1295 for synergy.

Research DosingⓘDoses from published scientific studies and clinical trials. May include human or animal research.

Scientific studies

Doses observed in research studies

Doses from Studies

100-300 mcg per injection

Clinical Trial Data - Investigational - Phase II trials completed ↗

200-300 mcg 2-3x daily

Clinical Trial Data - Investigational - Phase II trials completed ↗

Duration

8-12 weeks typical

Administration

Subcutaneous injection

Timing & Administration

Best Time to Take

Before bed or morning (fasted)

2-3 times daily, with main dose before bed

Food Recommendation

Take on empty stomach

Why This Timing?

GH secretagogues work best when taken fasted, as food (especially carbs/fats) blunts GH release. Evening dosing aligns with natural GH pulses during sleep.

Possible Side Effects

Not everyone experiences these effects. Individual responses vary based on dosage, duration, and personal factors.

●Generally well-tolerated
●Injection site reactions
●Headache
●Nausea
●Increased appetite
●Water retention
●Joint stiffness (temporary)
●Does not significantly elevate cortisol or prolactin
●Contraindicated with active malignancy

References

Research This Peptide Further

PubMed ClinicalTrials.gov FDA.gov

Buy in shop

Ipamorelin from $56/kit

3 verified vendors, ≥99% purity, COAs included.

Compare prices

Frequently Asked Questions

What does Ipamorelin do?

A selective growth hormone secretagogue that stimulates GH release without significantly affecting cortisol or prolactin. Considered one of the safest GHRPs.

How does Ipamorelin work?

Is Ipamorelin FDA approved?

No, Ipamorelin is not currently FDA approved. Current status: Investigational - Phase II trials discontinued. FDA Category 2 (pending reclassification to Category 1 per April 15, 2026 HHS announcement; remains Category 2 under current law until formal FDA rule; PCAC review July 23-24, 2026)

What are the side effects of Ipamorelin?

Reported side effects include: Generally well-tolerated, Injection site reactions, Headache, Nausea, Increased appetite. Individual responses vary based on dosage, duration, and personal health factors.

What is the typical dose of Ipamorelin?

Community-reported common dose: 200-300 mcg 2-3x daily (2-3x daily). Range: 100-500 mcg per dose. Administration: Subcutaneous injection. Community-reported doses. Not medical advice. Consult healthcare provider.

Related Peptides

Peptides commonly compared with Ipamorelin or used in similar applications.

CJC-1295 (No DAC)

Clinical Trials

A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.

Growth Hormone

GHRP-6

Clinical Trials

One of the first synthetic GH secretagogues developed. Strongly stimulates GH release and significantly increases appetite through ghrelin receptor activation.

Growth Hormone

GHRP-2

Clinical Trials

A synthetic hexapeptide that potently stimulates GH release. More potent than GHRP-6 with less appetite stimulation, but still elevates cortisol and prolactin.

Growth Hormone

MK-677

Clinical Trials

An orally active growth hormone secretagogue that mimics ghrelin. Although technically not a peptide, it is frequently discussed alongside GH peptides due to similar effects.

Growth Hormone

Tesamorelin

FDA

An FDA-approved GHRH analog used to reduce excess abdominal fat in HIV-infected patients with lipodystrophy. New F8 formulation (Egrifta WR) approved March 2025 allows weekly reconstitution vs daily.

Growth Hormone

Sermorelin

Preclinical

A truncated analog of natural GHRH containing the first 29 amino acids. Previously FDA-approved for pediatric GH deficiency, now used off-label for adult hormone optimization.

Growth Hormone

How to Use Ipamorelin Ipamorelin Alternatives Compare with Similar Browse All Peptides

Want updates on Ipamorelin research?

Subscribe to get notified when we add new research findings, protocol updates, and related peptide information.

Back to all peptides